LDS/Medical Tests/Des-Gamma-Carboxy Prothrombin (DCP), Serum

Des-Gamma-Carboxy Prothrombin (DCP), Serum

Hepatocellular carcinoma (HCC) is a common and aggressive liver cancer that typically develops in patients with chronic liver disease or cirrhosis. Des-gamma-carboxy prothrombin (DCP), also known as PIVKA-II, is an abnormal form of prothrombin produced when vitamin K–dependent carboxylation is impaired. In HCC, malignant hepatocytes produce increased amounts of DCP, leading to elevated serum levels.

Elevated DCP levels are strongly associated with aggressive tumor behavior, including vascular invasion, portal vein thrombosis, larger tumor burden, increased recurrence, and poorer survival. DCP provides diagnostic and prognostic information that complements alpha-fetoprotein (AFP) and AFP-L3, and combined use of these markers improves detection and risk stratification.

Advances in immunoassay technology have improved the sensitivity and specificity of DCP testing, allowing detection of early-stage disease. Measurement of serum DCP is therefore a useful tool for diagnosis, prognostication, and longitudinal monitoring of patients with hepatocellular carcinoma.

  • Screening and early detection of hepatocellular carcinoma in high-risk populations, including patients with chronic hepatitis or cirrhosis
  • Differential diagnosis of hepatocellular carcinoma from benign liver disease when used in conjunction with imaging and other tumor markers
  • Monitoring treatment response following surgical resection, locoregional therapy, or systemic therapy

Serum DCP levels at or above 7.5 ng/mL are associated with a significantly increased likelihood of hepatocellular carcinoma and have been linked to a substantially higher risk of disease development in high-risk populations.

Elevated levels are also associated with more aggressive tumor behavior and poorer outcomes. DCP levels below 7.5 ng/mL are associated with a lower probability of hepatocellular carcinoma but do not exclude early or small tumors.

Results should be interpreted in conjunction with imaging studies, AFP, AFP-L3, and clinical findings. Persistence or re-elevation of DCP following surgical or nonsurgical treatment is associated with increased risk of residual disease or tumor recurrence and warrants further clinical evaluation.

< 7.5 ng/mL

Quantitative immunoassay (e.g., enzyme immunoassay or electrochemiluminescence-based assay).

Serum, Serum separator tube (SST).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 3 weeks
AFP, Liver functional panel, calcium, CBC, glucose random, HBsAg, HCV Ab, liver biopsy, iron profile, lipid profile, alpha-1-antitrypsin, PT, serum electrolytes, GGT, LDH, renal function test, 5’-Nucleotidase.
1 to 4 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login